| Income Statement | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Research and development expenses | - | -6 | - | - |
| Operating loss | -353 | -123 | -610 | -405 |
| Financial (expenses) income, net | - | - | - | -130 |
| Other nonoperating expense | - | - | 41 | - |
| Financial expenses, net | -11 | 1 | - | - |
| Change in fair value of convertible loans and warrant liability | 358 | -44 | 139 | 716 |
| Loss before income tax benefit | - | -166 | -512 | - |
| Net profit (loss) | -6 | -166 | -512 | 181 |
| Net profit (loss) attributable to appyea inc | -6 | -166 | -512 | 181 |
| Basic | 0 | -0 | 0 | 0 |
| Diluted | 0 | -0 | 0 | 0 |
| Weighted average number of common shares outstanding basic | 534,758,474 | 527,945,974 | 483,923,616 | 453,450,254 |
| Weighted average number of common shares outstanding diluted | 534,758,474 | 527,945,974 | 483,923,616 | 453,450,254 |
APPYEA, INC (APYP)
APPYEA, INC (APYP)